SynCardia Systems, LLC (www.syncardia.com) in Tucson, AZ., is the privately-held manufacturer of the world's first and only FDA and Health Canada approved Total Artificial Heart. Intended for patients suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia Total Artificial Heart (STAH) is used as a bridge to transplant, helping patients to survive until a matching donor heart becomes available. SynCardia also develops a fully implantable version of the STAH.The SynCardia Total artificial Heart (STAH) may not be available in all markets. Please contact your SynCardia representative, or the Company (info@syncardia.com) if you have questions about the availability of the STAH in your area.

The Venture Office is an independent organization focused on providing clients with strategic and transactional advice in life science.

Acorai develops medical devices for non-invasive monitoring of intracardiac pressure with the aim to reduce re-hospitalizations due to heart failure, to lower mortality rates, and to improve patient's performance and quality of life.

Syntach AB is innovation-driven company based in Lund, Sweden. The Company develops an entirely new class of minimally invasive cardiac support devices and other products aimed and improving the lives of millions of patients living with advanced stage heart failure.

Scandinavian Real Heart AB is developing an artificial heart (total artificial heart, TAH) that mimics the body's natural circulation and can be used in patients waiting for a heart transplant. The Company's TAH design and performance is expected to provide patients with increased mobility and a better quality of life.

Occlutech Holding AG is a leading developer and manufacturer of proprietary, transcatheter devices for the repair of structural heart defects, the prevention of stroke, and treatment of heart failure symptoms. The Company markets and sells its products to hospitals and clinics in approximately 85 countries through its direct sales organization and via an international network of distribution partners. Occlutech has around 275 employees and owns manufacturing and R&D facilities in Jena, Germany and Istanbul, Turkey, with a global supply and customer support hub located in Helsingborg, Sweden. For more information, please visit www.occlutech.com.Key achievements included: Seven CE marks for novel Class III CV implants, leading the Group to over 300% growth in sales with 20% top-line growth, reaching positive EBIT, expanding product sales into over 75 international markets (Australia, Brazil, Canada, China, Japan, the United States, and others), and leading technology and company acquisitions.

Occlutech Ltd., a wholly owned subsidiary of Occlutech Holding AG, develops and manufactures proprietary products for pediatric and adult interventional cardiology uses, including the Atrial Flow Regulator (AFR) for patients with left or right heart failure. For more information, please visit www.occlutech.com.Key achievements included: Restructuring and turn around of the site, tripling of production capacity, turning site EBIT positive, building R&D hub that developed the AFR for heart failure and obtained five other CE marks for novel Class III CV implants and secured $MM in government R&D funding.

Procora was created to manage the global clinical and commercial development of the Atrial Flow Regulator (AFR), an innovative cardiac implant designed for use in patients with left or right heart failure. Key achievements included: building a start-up to develop the AFR device, successfully obtaining two Breakthrough Device Designations for the AFR, expanding clinical development, launching the procora website, creating marketing materials/corporate image, and launching digital marketing strategy.

NOLabs AB was a privately held MedTech company engaged in the development and commercialization of NitroSense technology for the administration and controlled release of nitric oxide gas. Key achievements: Re-aligned business from a focus on pain management to wound care, lead and managed the sale of NOLabs assets to an international wound-care company, re-aligned business from a focus on pain management to wound care.

M&A and investment banking advisory services for companies in the Life Sciences Sector.Key achievements included: securing over half a dozen advisory mandates including NOLabs, managed the sale of >$7MM neurostimulation assets to Cyberonics (LivaNova).

GammaCan was a U.S.-Israeli, small-cap biotechnology company engaged in the clinical development of cancer immunotherapy for the treatment of melanoma. The Company was sold in 2008.Key achievements included: Raising $6.4MM and obtaining Orphan Drug Status.

New York-based investment advisory firm focused on global life science and healthcare sectors.Key achievements included: Expanding the bank’s reach into the Israeli biotech market and leading M&A for small-cap biotechs in Australia, and Europe.

New York-based investment bank focused on financing public companies in the global life science and healthcare sectors.Key achievements included: Raising over $50MM for small-cap biotech in PIPES, secondaries & reverse mergers.

New York-based investment advisory firm and hedge fund focused on global life science and healthcare sectors.Key achievements included: 48.9% return on portfolio companies.

Global Management Consulting firm.Key achievements included: Lead role in formulating discovery strategy to monetize human genome for major Genomics company, the lead role in sale and execution of brain cancer therapy development strategy for leading U.S. clinic, and lead role in creating Best Practice / Industry Benchmarking documents on R&D Productivity.

Consulting firm specialized in licensing and acquisition, due diligence, IP portfolio construction, business opportunity assessment, product clearance (FTO), and patent litigation.Key achievements include: Leading the firm’s expansion into the Biotech & Medical Devices sectors and selling projects worth over $5MM.